Abstract
Capuramycin (CM) antibiotics are bactericidal for Mycobacterium tuberculosis (MTB) in vitro. Due to their low membrane permeability and efflux, however, these compounds are less effective against intracellular MTB. To improve intracellular activity, we created phospholipid Phosal 53 MCT-based nanoemulsion (NE) formulations of CM analogues SQ641, SQ641-aua, SQ641-2aua and SQ997-3aua. We assessed intracellular killing activity of the 4 CM analogues and their NE formulations against MTB using the J774A.1 mouse macrophage cell line. Of the several emulsifiers investigated, d-tocopheryl polyethylene glycol 1000 succinate (TPGS) produced the most efficacious and stable emulsion, with a mean particle size below 70 nm. CM analogue-NE formulations prepared using TPGS as emulsifier (-NETPGS) showed significantly improved intracellular activity over free drugs. The order of intracellular activity was SQ641-2aua- NETPGS > SQ997-3aua-NETPGS > SQ641-aua-NETPGS > SQ641-NETPGS. At 2× MIC the intracellular killing activity of SQ641- 2aua-NETPGS, the most active formulation, surpassed that of first-line anti-TB drugs isoniazid (INH), rifampin (RIF) and ethambutol (EMB). Enhanced intracellular activity of the -NETPGS formulation, perhaps, was due to TPGS mediated blocking of the drug efflux.
Keywords: Anti-TB drugs, SQ641, phospholipids, nanoemulsion, M.tuberculosis, intracellular activity, capuramycin, Intracellular Drug Activity, CM Analogues, emulsifiers
Drug Delivery Letters
Title: Nanoemulsion Formulation Enhances Intracellular Activity of Capuramycin Analogues against Mycobacterium Tuberculosis
Volume: 1 Issue: 2
Author(s): Venkata M. Reddy, Elena Bogatcheva, Leo Einck and Carol A. Nacy
Affiliation:
Keywords: Anti-TB drugs, SQ641, phospholipids, nanoemulsion, M.tuberculosis, intracellular activity, capuramycin, Intracellular Drug Activity, CM Analogues, emulsifiers
Abstract: Capuramycin (CM) antibiotics are bactericidal for Mycobacterium tuberculosis (MTB) in vitro. Due to their low membrane permeability and efflux, however, these compounds are less effective against intracellular MTB. To improve intracellular activity, we created phospholipid Phosal 53 MCT-based nanoemulsion (NE) formulations of CM analogues SQ641, SQ641-aua, SQ641-2aua and SQ997-3aua. We assessed intracellular killing activity of the 4 CM analogues and their NE formulations against MTB using the J774A.1 mouse macrophage cell line. Of the several emulsifiers investigated, d-tocopheryl polyethylene glycol 1000 succinate (TPGS) produced the most efficacious and stable emulsion, with a mean particle size below 70 nm. CM analogue-NE formulations prepared using TPGS as emulsifier (-NETPGS) showed significantly improved intracellular activity over free drugs. The order of intracellular activity was SQ641-2aua- NETPGS > SQ997-3aua-NETPGS > SQ641-aua-NETPGS > SQ641-NETPGS. At 2× MIC the intracellular killing activity of SQ641- 2aua-NETPGS, the most active formulation, surpassed that of first-line anti-TB drugs isoniazid (INH), rifampin (RIF) and ethambutol (EMB). Enhanced intracellular activity of the -NETPGS formulation, perhaps, was due to TPGS mediated blocking of the drug efflux.
Export Options
About this article
Cite this article as:
M. Reddy Venkata, Bogatcheva Elena, Einck Leo and A. Nacy Carol, Nanoemulsion Formulation Enhances Intracellular Activity of Capuramycin Analogues against Mycobacterium Tuberculosis, Drug Delivery Letters 2011; 1 (2) . https://dx.doi.org/10.2174/2210304x11101020150
DOI https://dx.doi.org/10.2174/2210304x11101020150 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tuberculosis and HIV Coinfection–the Challenge in the Prevention, Detection and Treatment of Tuberculosis
Current Bioinformatics Mangrove Plants as a Source of Bioactive Compounds: A Review
The Natural Products Journal The Methylerythritol Phosphate (MEP) Pathway for Isoprenoid Biosynthesis as a Target for the Development of New Drugs Against Tuberculosis
Current Medicinal Chemistry Biocombinatorial Selection of Carbohydrate Binding Agents of Therapeutic Significance
Current Drug Discovery Technologies Atypical Chemokine Receptors in Inflammatory Disease
Current Molecular Medicine Synthetic Peptides for the Immunodiagnosis of Human Diseases
Current Medicinal Chemistry Graphical Abstracts:
Letters in Drug Design & Discovery Antimicrobial Evaluation of 5-Substituted Aryl 1H-Tetrazoles
Medicinal Chemistry <i>In Silico</i> Vaccine Designing Targeting the Virulence Factors of mce Operons of <i>Mycobacterium avium</i> subsp. <i>Paratuberculosis</i>
Current Proteomics Synthesis, In vitro and In silico Studies of Benzothiazole Azo-Ester Derivatives as Anti-TB Agents
Anti-Infective Agents An Overview on Chemistry and Biological Importance of Pyrrolidinone
Current Organic Synthesis Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Drug Delivery Letters Asthma and High Altitude: Is It Safe to Be and Work?
Current Respiratory Medicine Reviews Immunity to Tuberculosis and Novel Therapeutic Strategies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Host-Pathogen Interactions Made Transparent with the Zebrafish Model
Current Drug Targets Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis
Current Drug Targets A Comparison of Non-Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery
Current Drug Metabolism Vitamins Mediate Immunological Homeostasis and Diseases at the Surface of the Body
Endocrine, Metabolic & Immune Disorders - Drug Targets Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Editorial [Hot Topic: Carbonic Anhydrases: Again, and Again, and Again (Executive Editor: Claudiu T. Supuran)]
Current Pharmaceutical Design